Table 2.
Treatment received.
| Treatment type | N | % |
|---|---|---|
| Surgery* (N = 121) | ||
| Partial mastectomy | 63 | 52.1 |
| Total mastectomy | 58 | 47.9 |
| Sentinel lymph node | 70 | 57.9 |
| Axillary node dissection | 101 | 83.5 |
| Chemotherapy$ (N = 114) | ||
| Adjuvant | 61 | 53.5 |
| Neo-adjuvant | 29 | 25.4 |
| Any/at any time | 88 | 77.2 |
| Hormone therapy$ (N = 114) | ||
| Any drug | 93 | 81.6 |
| Tamoxifen-based | 36 | 31.6 |
| Aromatase inhibitor-based | 49 | 43.0 |
| Other | 8 | 7.0 |
| Radiotherapy*(N = 121) | ||
| Breast or chest wall PTV | 121 | 100.0 |
| D50% (mean ± SD) (Gy) | 49.7 ± 1.3 | |
| D95% (mean ± SD) (Gy) | 46.2 ± 4.3 | |
| D2% (mean ± SD) (Gy) | 56.3 ± 4.4 | |
| Concomitant Boost PTV | 67 | 55.4 |
| D50% (mean ± SD) (Gy) | 59.4 ± 1.6 | |
| D95% (mean ± SD) (Gy) | 56.9 ± 1.8 | |
| D2% (mean ± SD) (Gy) | 61.5 ± 1.6 | |
| Internal mammary chain PTV | 113 | 93.4 |
| D50% (mean ± SD) (Gy) | 49.4 ± 2.6 | |
| D95% (mean ± SD) (Gy) | 46.6 ± 5.3 | |
| D2% (mean ± SD) (Gy) | 52.1 ± 2 | |
| Subclavicular PTV | 110 | 90.9 |
| D50% (mean ± SD) (Gy) | 49.5 ± 2.2 | |
| D95% (mean ± SD) (Gy) | 46.8 ± 3.1 | |
| D2% (mean ± SD) (Gy) | 51.9 ± 1.6 | |
| Supraclavicular PTV | 110 | 90.9 |
| D50% (mean ± SD) (Gy) | 49.4 ± 2.1 | |
| D95% (mean ± SD) (Gy) | 46.6 ± 3.3 | |
| D2% (mean ± SD) (Gy) | 52 ± 1.5 | |
*By treated breast.
$By patient.
PTV: planning target volume.
Dx %: dose received by at least x% of the volume.